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Regulator of G-protein signaling 9-2 (RGS9-2), a member of the RGS family of GGTPase accelerating proteins, is expressed specifically
in the striatum,whichparticipates in antipsychotic-induced tardivedyskinesia and in levodopa-induceddyskinesia.We report thatRGS9
knock-out mice develop abnormal involuntary movements when inhibition of dopaminergic transmission is followed by activation of
D2-like dopamine receptors (DRs). These abnormal movements resemble drug-induced dyskinesia more closely than other rodent
models. Recordings from striatal neurons of these mice establish that activation of D2-like DRs abnormally inhibits glutamate-elicited
currents. We show that RGS9-2, via its DEP domain (for Disheveled, EGL-10, Pleckstrin homology), colocalizes with D2DRs when coex-
pressed in mammalian cells. Recordings from oocytes coexpressing D2DR or the m2 muscarinic receptor and G-protein-gated inward
rectifier potassium channels show that RGS9-2, via its DEP domain, preferentially accelerates the termination of D2DR signals. Thus,
alterations in RGS9-2 may be a key factor in the pathway leading from D2DRs to the side effects associated with the treatment both of
psychoses and Parkinson’s disease.
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Introduction
Drugs that are effective in the treatment of psychoses (Sawa and
Snyder, 2002; Freedman, 2003) and Parkinson’s disease (Dauer
and Przedborski, 2003) are antagonists (antipsychotics) or ago-
nists [dopamine/L-3,4-dihydroxyphenylalanine (L-DOPA)], re-
spectively, of G-protein-coupled D2-like dopamine receptors
(DRs). The receptors for dopamine are members of the seven
transmembrane-spanning G-protein-coupled receptor (GPCR)
superfamily and may be classified into two subfamilies, D1-like
(D1 and D5, which activate intracellular heterotrimeric Gs
G-proteins) and D2-like (D2, D3, and D4, which activate hetero-
trimeric, pertussis toxin-sensitive Gi andGoG-proteins) (Missale
et al., 1998). Typical antipsychotics and dopamine receptor ago-
nists also both induce motor side effects, tardive and L-DOPA-
induced dyskinesia, which result from their actions on D2-like
DRs in the striatum, an important component of the basal ganglia
loop that controls movement. Although the pathophysiology re-
mains obscure, thesemotor side effects are strikingly similar with
respect to clinical phenomenology, epidemiology, and risk fac-
tors (Rascol and Fabre, 2001).
When an activated GPCR (e.g., dopamine-bound D2DR) en-
counters a trimeric G-protein, it catalyzes the exchange of GTP
for GDP at the  subunit of the G-protein (G), leading to the
dissociation of the GTP-bound G subunit from the G dimer.
The activated GTP-bound G subunit and the freed G dimer
regulate the activity of diverse cellular effector molecules. Signal
termination is mediated by the intrinsic GTPase activity of the
G, which hydrolyzes the bound GTP to GDP, allowing it to
reassociate with the G dimer (Ross and Wilkie, 2000).
The GTPase activity of G and hence GPCR signal termina-
tion can be enhanced by members of a family of proteins called
regulators of G-protein signaling (RGSs) (Berman and Gilman,
1998; De Vries et al., 2000; Ross and Wilkie, 2000). All RGS pro-
teins have a conserved core “RGS domain” of120 amino acids,
which is necessary and sufficient for their GTPase stimulating
action. Many RGS proteins also possess additional C- and
N-terminal modular protein-binding domains and motifs.
Transcripts of an RGS protein, the RGS9 splice variant
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RGS9-2, are confined to the striatum (Thomas et al., 1998; Rah-
man et al., 1999), the brain region involved in antipsychotic-
induced tardive dyskinesia and in levodopa-induced dyskinesia.
Recently, Rahman et al. (2003) reported that mice with a null
mutation in the RGS9 gene showed heightened locomotor re-
sponses to cocaine and related psychostimulants and that, con-
versely, viral-mediated overexpression of RGS9-2, but not RGS4,
in rat striatum specifically reduced locomotor responses toD2DR
agonists.
The results described above prompted us to search for associ-
ations between D2DRs and RGS9-2. The N termini of both RGS9
splice variants possess a highly conserved DEP domain (for Di-
sheveled, EGL-10, Pleckstrin homology) (De Vries and Gist Far-
quhar, 1999;Druey, 2001). DEP domains are present inmany key
signaling proteins, but the function of this domain is not clear
(Ponting and Bork, 1996). In this study, we show that the RGS9
DEP domain mediated subcellular colocalization with D2DRs.
We demonstrate that such localization has functional conse-
quences at the cellular level and implicate a role for RGS9-2 in
suppressing the extrapyramidal side effects of antipsychotic treat-
ment and the movement disorders of Parkinson’s disease.
Materials andMethods
Knock-out mice. RGS9/mice were generated as described by Chen et
al. (2000). All experimental procedures complied with National Insti-
tutes of Health guidelines as approved by the Institutional Animal Care
and Use Committee of the California Institute of Technology (Pasadena,
CA) or the University of Leipzig (Leipzig, Germany).
Drug treatment. Reserpine, haloperidol, apomorphine, quinpirole,
SKF 38393, or saline were administered intraperitoneally. Reserpine (1
mg/kg), haloperidol (5 mg/kg), or saline were administered once a day
for 3 consecutive days. Behavioral testing with apomorphine (1 mg/kg),
quinpirole (10 mg/kg), or SKF 38393 (10 mg/kg) was performed imme-
diately before reserpine or haloperidol treatment and 3 d after the final
injection of either drug.
Recording of locomotion and abnormal involuntary movements. Loco-
motion was measured using a cage rack system with infrared light beams
(San Diego Instruments, San Diego, CA). Single events represented dis-
ruption of two individual light beams 10 cm apart. Data were recorded
for 15 min before and after drug application. The abnormal involuntary
movements (AIMs) were evaluated immediately after administration of
dopamine receptor agonists. The AIMs were classified into the following
four subtypes (Cenci et al., 2002; Lundblad et al., 2002): (1) axial AIMs
consisting of dystonic posturing and choreiform twisting of head or neck;
(2) limb movements consisting of rapid jerky movements of front limbs
or hindlimbs; (3) orofacial movements including abnormal chewing,
licking, grooming, etc.; and (4) abnormal locomotion comprising un-
steady gait (secondary to dystonia), moving backwards, and jumping.
Each of these four subtypes was scored on a severity scale from 0 to 4 (1,
present during25% of the observation time; 2, present between 25 and
50% of the observation time; 3, present between 50 and 75% of the
observation time; and 4, present75% of the observation time).
Electrophysiology in acute striatal slices. Anesthetized (halothane) mice
(postnatal days 10–25) were decapitated, and brains were placed in an
ice-cold artificial CSF (ACSF). Coronal slices (300 m thick) containing
striatum and globus pallidus were cut with a VT1000S vibratome (Leica,
Nussloch, Germany) and stored in bubbled ACSF with kynurenic acid (1
M) for 30 min and without kynurenic acid for at least an additional 30
min. During recordings, slices were perfused with ACSF (containing, in
mM: 126 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 26 NaHCO3,
25 D-glucose, pH 7.3, bubbled with 95% O2 and 5% CO2) at 32–33°C.
More than 90% of striatal neurons aremedium spiny GABAergic projec-
tion neurons. Recordings were performed on these neurons, which were
identified (Axioskop infrared differential interference contrast videomi-
croscopy; Zeiss, Jena, Germany) by their small size and irregular shape
(densely arborizing recurrent axon collaterals). Medium spiny neurons
have two electrophysiological states, a down state with restingmembrane
potentials below 80 mV and no spontaneous activity and an up state
with resting membrane potentials above 80 mV and high-frequency
spontaneous action potentials (10–15Hz) (Blackwell et al., 2003). In our
experiments,90%of the cells were in the down state. However, specific
cell types were not identified using dye injection and immunocytochem-
istry. Thus, we cannot exclude that some recordings were obtained from
other cell types such as GABAergic interneurons. These fast-spiking in-
terneurons are difficult to distinguishmorphologically and are also silent
at rest but spike at very high frequencies (up to 200 Hz after excitation).
In addition, recordings aimed at these cells are only successful in1 in 60
cells in striatal slice recordings (Centonze et al., 2003). Thus, it is likely
that nearly all of our recordings were done in medium spiny projection
neurons. These neurons have been divided into two groups based on
anatomical and biochemical observations and separated into projection
neurons giving rise to a direct pathway (projecting to internal globus
pallidus) or an indirect pathway (projecting to external globus pallidus)
(Gerfen, 1992). Recent studies have suggested that D2-like dopamine
receptors are present in both groups of medium spiny striatal neurons
(Kawaguchi et al., 1990; Surmeier et al., 1996; Aizman et al., 2000; Nicola
et al., 2000). Large cholinergic interneurons were excluded by size and
lack of a hyperpolarization-activated cation current (Ih).
Patch electrodes were pulled (Narishige pipette puller, Tokyo, Japan)
fromborosilicate glass and filled with a solution containing the following
(in mM): 144 K gluconate, 3 MgCl2, 10 HEPES, 0.2 EGTA, pH 7.2. The
resistance of the electrodes was between 3 and 9 M. Series resistance
was compensated 70–85% using lag values of 7–8 s. Recordings were
low-pass filtered at 2 kHz and digitized on-line at 20 kHz (DigiData 1322;
pClamp9 software; Axon Instruments, Union City, CA). All drugs were
dissolved inACSF and applied using an eight-channel application system
(BioMedical Instruments, Zulpich, Germany).
Antibodies. Three anti-D2DR antibodies were used: a goat polyclonal
IgG directed against the extracellular epitope in theN terminus of D2DR,
a rabbit polyclonal IgG also directed against an extracellular epitope
(catalog #sc-7522 and sc-9113, respectively; Santa Cruz Biotechnology,
Santa Cruz, CA), and another rabbit polyclonal IgG from Research and
Diagnostics (Berkeley, CA) (catalog #AS-3526S, used in striatal immu-
nohistochemistry). The anti-RGS9 antibody (also used in striatal immu-
nohistochemistry) was a goat antibody from Santa Cruz Biotechnology
(catalog #sc-8142). The anti-m1-muscarinic acetylcholine receptor (m1-
mAChR) antibody (catalog #AMR-001) was a rabbit polyclonal from
Alomone Labs (Jerusalem, Israel), and the anti-m2-mAChR antibody
(catalog #AB5166) was a rat monoclonal IgG from Chemicon (Te-
mecula, CA). All secondary antibodies were from Jackson ImmunoRe-
search (West Grove, PA).
Striatal immunohistochemistry. Dissected mouse brains were prefixed
in 4% paraformaldehyde dissolved in PBS, pH 7.4, for 1 h at 4°C. The
fixed brains were then protected in 30% sucrose in PBS for 30 min.
Horizontal sections were cut at 20 m. Before staining, sections were
postfixed in 1:1 methanol/acetone for 10 min at room temperature and
rehydrated in two changes of PBS (5 min each). Sections were blocked
with 1% fish gelatin (Sigma-Aldrich, St. Louis, MO) in PBS at room
temperature in a humid box for 1 h. Slides were incubated with 1:50
dilution of primary anti-D2DRand anti-RGS9-2 in 1% fish gelatin in PBS
at room temperature for 4 h. Sections were washed in PBS three times (5
min each wash) and were then incubated with the appropriate secondary
antibody diluted in blocking solution. D2DR was visualized using a
highly cross-absorbed cyanine (Cy) 2-conjugated secondary anti-rabbit
antibody, and RGS9-2 was visualized using a highly cross-absorbed Cy5-
conjugated secondary anti-goat antibody (see antibody descriptions
above). Sections were washed twice in PBS (10 min each wash) and
mounted on cover slides using 50% glycerol in PBS.
cDNA clones and constructs. The cDNA for the D1DR, human and the
D2DR, human, long and short forms, were provided by M. G. Caron
(DukeUniversity, Durham,NC). TheRGS9-2 clonewas provided by E. J.
Nestler (University of Texas Southwestern Medical Center, Dallas, TX)
(Rahman et al., 1999). The other cDNA clones used have been described
previously (Kovoor et al., 2000). Enhanced green fluorescent protein
(EGFP) cDNA was from Clontech (Palo Alto, CA). The “DEPless
RGS9-2” construct was created by deleting from the full-length RGS9-2 a
2158 • J. Neurosci., February 23, 2005 • 25(8):2157–2165 Kovoor et al. • D2 Dopamine Receptor and RGS9-2 Colocalization
segment (residues 2–220) that contained just the DEP domain. Visual-
ization of full-length RGS9-2 and DEPless RGS9-2 distribution was fa-
cilitated by C-terminal fusion of EGFP via a flexible linker sequence:
GSGGGSG. The RGS9 DEP domain construct consisted solely of the
RGS9DEPdomain (residues 30–110 of RGS9) fused to theN terminus of
EGFP via the spacer sequence: GDPPVAT. All constructs were engi-
neered using standard molecular biology techniques and are shown in
Figure 3.
Cell transfection and immunostaining. Cells (all lines were from Amer-
ican Type Culture Collection, Manassas, VA) were transfected with
cDNA using Lipofectamine (Invitrogen, Carlsbad, CA) according to the
manufacturer’s recommendations. Cells were prepared for transfection
by culturing to 60% confluence in 30 mm poly-L-lysine-coated glass-
bottom dishes (MatTek, Ashland, MA). Dishes were incubated for 2 h
with 50 g/ml poly-L-lysine (average molecular weight, 25,000; Sigma-
Aldrich) in 15 mM sodium borate buffer, pH 8.4, and were then rinsed
three times with sterile water. Twenty-four hours after transfection, the
cells were fixed and stained in the following manner. Cells were fixed by
treating with 4% paraformaldehyde (Sigma-Aldrich) freshly dissolved in
PBS. Cells were made permeable by treating with PBS containing 0.2%
Triton X-100 (Sigma-Aldrich) for 4 min. Nonspecific antibody binding
sites were masked by incubating in blocking solution consisting of a
solution 1% fish gelatin (Sigma-Aldrich) and 1% hydrolyzed casein
(Sigma-Aldrich) in PBS for 30 min. Cells were then incubated with the
appropriate primary antibody for 1 h at 37°C followed by incubation
with the corresponding fluorophore-conjugated secondary antibody for
another hour at 37°C. Antibody dilutions and incubations were per-
formed in blocking solution. Cells were washed four times with PBS (5
min each wash) before and after every one of the above treatments.
Finally, the cells were mounted by overlaying with 50% glycerol solution
in PBS and stored at20°C.
Specificity of antibodies and fluorescent signals. Control experiments to
confirm specificity and validity of fluorescent signals were as follows.
Primary antibody specificity was evaluated by comparing immunostain-
ing in cells that were transfected with cDNA for the target protein with
sham-transfected cells. No signal was observed in sham-transfected cells
for any of the primary antibodies used. The specificity of the primary
antibody signal was further confirmed by ensuring that transfected cells
were not stained using normal serum from the species used to raise the
antibody. Specificity of the RGS9-2 antibody was further validated by
determining absence of immunostaining in striatum from RGS9 knock-
out mice. Cells were also stained directly with the fluorophore-
conjugated secondary antibody in the absence of the primary antibody.
Insignificant fluorescent signal was noted in all of these control experi-
ments. Thus, all the secondary antibodies used reacted only with the
appropriate primary antibody and not with cellular antigens. Images of
the control tissue were collected with the same settings used for the
labeled tissue.
Confocal microscopy. All images were obtained using a Leica TCS laser
scanning spectral inverted confocal microscope (Leica Microsystems,
Bannockburn, IL) with a 40 oil immersion objective (for striatal im-
munohistochemistry) or a 100 oil immersion objective (all other im-
ages). EGFP and Cy2 were excited with the 488 nm line from an argon
laser, Cy3 was excited with the 568 nm line from a krypton laser, and Cy2
was excited using the 633 nm line from a helium–neon laser. Emitted
fluorescence was spectrally dispersed using a prism, and the spectral
window for data collection by the photomultiplier tube was defined us-
ing adjustable slits. EGFP and Cy2 signals were collected using a spectral
window that extended from 495 to 510 nm. Cy3 signals were collected
using a spectral window that extended from 585 to 600 nm. Cy5 signals
were collected using a spectral window that extended from 665 to 675
nm. The pinhole was set at 1 Airy unit. Images were collected at a
resolution of 1024 1024 pixels using the slowest scan-speed setting for
the microscope. Only one of the fluorophores was excited (by activation
of just the one corresponding laser line) during each image acquisition
scan, and so the dual images from double-labeled cells were obtained
sequentially instead of simultaneously. Using these conditions, we were
able to ensure that there was no “bleed-through” of signal from one
fluorophore into the collection window of the other in double-labeling
experiments. Absence of bleed-through was confirmed by sequentially
imaging cells labeled with only one of the pair of fluorophores. In these
control experiments, no bleed-through was observed even as the laser
power was increased 500% over that used to collect the images in the
coexpression experiments.
Oocyte culture and cRNA preparation and injection. Xenopus oocyte
preparation was described previously (Kovoor et al., 2000). cRNA was
synthesized in vitro fromplasmids containing the cDNA and appropriate
promoters for cRNA transcription. Plasmids were linearized before
cRNA synthesis, andmMessageMachine kits (Ambion, Austin, TX)were
used to generate capped cRNA. cRNA was injected into oocytes at a
volume of 25 nl per oocyte using a Drummond microinjector. Oocytes
were maintained in a saline buffer (containing, in mM: 96 NaCl, 2 KCl, 1
MgCl2, 1 CaCl2, and 5 HEPES, pH 7.5) solution supplemented with
sodium pyruvate (2.5 mM) (Sigma-Aldrich) and gentamycin (50 g/ml)
(Sigma-Aldrich).
Oocyte electrophysiology. Two-electrode voltage-clamp experiments
were performed 36–72 h after cRNA injection. Membrane potential was
clamped at 80 mV using a GeneClamp 500 amplifier and pClamp 6
software (Axon Instruments). A valve system controlled by the data ac-
quisition software, pClamp 6, was used to control solution changes and
to minimize wash-in and wash-out times. Electrodes were filled with 3 M
KCl and had resistances of 0.5–1.5 M. To reveal currents through the
inwardly rectifying G-protein-gated inward rectifier potassium (GIRK)
channels, recordings were performed in oocyte saline buffer with ele-
vated (16mM) KCl concentration (other components, in mM: 82 NaCl, 1
MgCl2, 1 CaCl2, and 5 HEPES, pH 7.5). Kinetic analysis and curve fitting
were performed using pClamp 6 software. Exponentials were fit to the
activation and deactivation phases of the GIRK currents. Cursors were
positioned at points on the activation and deactivation curves that cor-
responded to 20 and 80% of the maximum equilibrium responses, and
the exponentials were fitted to the portions of the current trace between
these two points.
Results
RGS9-2 attenuates motor behavior related to
upregulated D2DR
We treated RGS9 knock-out mice and wild-type mice with reser-
pine, which depletes dopamine from nerve terminals, or with the
antipsychotic haloperidol, a specific antagonist of D2-like DRs
(see Materials and Methods). Both reserpine and haloperidol
treatments can selectively produce supersensitivity of striatal D2-
like DRs (LaHoste andMarshall, 1994). We observed no obvious
behavioral differences between drug-naive RGS9 knock-out ani-
mals and wild-type littermates. Reserpine treatment for 3 d (see
Materials and Methods) produced a comparable loss of sponta-
neous locomotion in both groups (data not shown). However,
after reserpine or haloperidol treatment, dopaminergic agonists
(quinpirole, selective agonist of D2-like DRs or apomorphine,
nonselective agonist of D1- and D2-like DRs) produced severe
AIMs (Fig. 1A,C) (see also http://orphanin.caltech.edu/lester/
world/Videos%20for%20RGS9%20JNS%20paper/ for video
clips) only in the RGS9-deficient mice (AIM score, 4; see Ma-
terials and Methods). Gait alterations included excessive side-
ward and backward motions. These animals also had difficulties
maintaining an upright posture and repeatedly hit the cage wall.
There were frequent rapid jerky movements, predominantly of
hindlimbs. Most animals also showed an excessively bent trunk
resembling dystonia. Apomorphine and quinpirole also pro-
duced a greater increase in locomotion after reserpine in the
RGS9 knock-out mice (Fig. 1B). The genetic ablation of RGS9
did not affect D1 dopamine receptor-related behavior: the D1DR
agonist SKF 38393, after reserpine or haloperidol, elicited com-
parable mild orofacial AIMs and locomotion in both wild-type
and knock-out animals (Fig. 1A–C). These data suggest that the
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observed AIMs result from the perturba-
tion of a D2-like DR-specific cellular
pathway.
Administration of dopaminergic ago-
nists before reserpine or haloperidol treat-
ment produced few AIMs (mean AIM,1
in both groups) in either wild-type or
RGS9-null animals. In accordance with
previous reports (LaHoste and Marshall,
1994; LaHoste et al., 2000), relevant AIMs
were not observed in either set ofmice pre-
treated with vehicle injections for 3 d and
subsequently challenged with quinpirole
(10 mg/kg).
The relatively short duration of reser-
pine or haloperidol treatment (3 d) may
explain why significant increases in loco-
motion after reserpine or after haloperidol
only occurred in response to apomorphine
and only in RGS9 knock-out mice.
Previously, double-labeling in situ hy-
bridization experiments suggested that
RGS9-2 transcripts are expressed in those
striatal neurons that might also express
D2DR (Rahman et al., 2003). Immunos-
tains of striatal sections confirmed that
there was a significant degree of overlap of
D2DR and RGS9-2 protein expression in
the striatum (Fig. 1D).
A role for RGS9-2 in cellular signaling of
D2-like DR in vivo and implications for
synaptic modulation
Previously, we helped to show that D2DR
activation produced a significantly greater
inhibition of forskolin-stimulated adeny-
lyl cyclase activity in striatal extracts from RGS9 knock-out ani-
mals compared with their wild-type littermate controls (Rahman
et al., 2003). The striatal medium spiny neurons that express
D2-class dopamine receptors and RGS9-2 receive excitatory glu-
tamatergic inputs from the cortex in addition to the dopaminer-
gic inputs from the substantia nigra (Gerfen, 1992). Therefore,
we investigated whether the activation of D2-like DRs could
modulate glutamate-elicited conductances in these cells. Appli-
cation of glutamate (100 M) to voltage-clamped medium spiny
neurons in slice preparations from either wild-type or RGS9-null
mice activated robust inward currents (Fig. 2A,B). These cur-
rents desensitized partially during a 6 s glutamate application
(Fig. 2A,B). The desensitization was transient, and the response
recovered after 3 min of glutamate-free wash. Coapplication
of 1–100 M quinpirole, a selective agonist of D2-like DRs, sig-
nificantly inhibited the peak amplitude of the glutamate-elicited
response in RGS9 null neurons, whereas there was no significant
reduction by quinpirole in wild-type cells (Fig. 2A,B). Although
quinpirole concentrations10Mmay affect targets in addition
to D2DR, it is notable that statistically significant inhibition of
glutamate-elicited currents in the knock-out animals were ob-
served both at 1 and 10 M quinpirole (Fig. 2B). The fraction of
RGS9-null cells that showed25% inhibition of glutamate (100
M)-induced currents was 0.5 at 1M and increased to 0.67 at 10
M and 1.0 at 100 M. In contrast, the fraction of wild-type cells
in which the glutamate-elicited currents were inhibited 25%
was 0.22 (1 and 10 M quinpirole) or 0.44 (100 M quinpirole).
Application of quinpirole alone produced no changes in mem-
brane conductance of eitherwild-type or RGS9-null neurons.We
used 100 M quinpirole to study effects on NMDA- or AMPA-
induced currents because we detected the most striking differ-
ences between genotypes at this concentration. NMDA receptors
accounted for the component of glutamate-evoked currents
modulated by quinpirole in the RGS9-null cells, because 100 M
quinpirole significantly inhibited NMDA-elicited (100 M) but
not AMPA-elicited (10M) currents (Fig. 2C). Finally, the inhib-
itory effects of quinpirole were blocked by the specific D2-like DR
antagonist sulpiride, confirming that they were mediated via D2-
like DRs.
The abnormal inhibition of glutamate-elicited currents byD2-
like DRs in the absence of RGS9 was not a result of increased
expression of glutamate receptors, because the amplitude of the
glutamate responsewas not increased in RGS9-null neurons (Fig.
2). These data suggest that in wild-type neurons, RGS9-2 blocks
D2-like DR-mediatedmodulation of conductances elicited by ac-
tivation of NMDA receptors. Because it seemed unlikely that this
effect arises solely from the GTPase-enhancing activity of
RGS9-2, we explored other functional associations between
RGS9-2 andD2DRs, themost abundantly expressedD2-like DRs.
D2DR, RGS9-2 colocalization
RGS9-2 and D2DRs were expressed in vitro in Chinese hamster
ovary (CHO) cells and visualized using confocalmicroscopy. The
D2DR expression was visualized by immunostaining CHO cells
with the anti-D2DR antibody after they were first made perme-
Figure 1. Behavioral effects of dopamine agonists in reserpinized or haloperidol-treated mice and distribution of D2DR and
RGS9-2 in wild-type striatal neurons. Mice were injected once per day for 3 d with reserpine or haloperidol (see Materials and
Methods). Threedays after recovery, themicewere injectedwithdopaminergic agonists. Openbars representwild-typemice, and
filled bars represent RGS9-deficient mice. A, Quantification of abnormal involuntary movements in reserpinized mice after apo-
morphine (apo; n 13 and 18 in wild-type and knock-out, respectively), quinpirole (quin; n 10, 14), or SKF 38393 (SKF; n
9, 8) injection (# and * indicate significant differences between genotypes; p  0.01; Wilcoxon rank test). B, Locomotion
measured (for 15min) in the reserpinizedmice (fromA) immediately before (baseline) and after apo, quin, or SKF injection (*p
0.01; t test). C, Quantification of AIM in haloperidol-treated mice after quin or SKF injection (n 10; *p 0.01; Wilcoxon rank
test).D, D2DRdistribution (red; left), RGS9-2distribution (green;middle), and their overlay (right) in a striatal section. The left and
middle panels represent sequential confocal scans of the same field. E, D1DR distribution (red; left), RGS9-2 distribution (green;
middle), and their overlay (right) in a striatal section. The left andmiddle panels represent sequential confocal scans of the same
field. Scale bar: (in D) D, E, 10m. Error bars represent SEM.
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able using the detergent Triton X-100 (see Materials and Meth-
ods). Using this same protocol, identical staining patterns were
obtained using three separate antibodies that were directed
against different intracellular and extracellular epitopes within
D2DR. NoD2DR immunostain was observed in dishes not trans-
fected with D2DR cDNA.
To observe RGS9 distribution, we used anRGS9-2 fusion con-
struct, RGS9-2–EGFP, in which the EGFP was attached to the C
terminus of the full-length striatally expressed RGS9 isoform,
RGS9-2 (Fig. 3) (see Materials and Methods).
The D2DR expression pattern in CHO cells (Fig. 4A) was
consistent with previous studies showing that80%of theD2DR
expressed in several cell types, including human embryonic kid-
ney (HEK) 293T, COS-7, and HeLa, resides within intracellular
compartments (Prou et al., 2001). It was also consistent with our
observations in striatal neurons in whichD2DR is in extranuclear
accumulations (compare Figs. 1D, 4A). In CHO cells transfected
solely with the RGS9-2 cDNA, the RGS9-2 protein was distrib-
uted uniformly throughout the cytoplasm (Fig. 4B). However,
when CHO cells were transfected with cDNA for both D2DR and
the RGS9-2, we found that the expression pattern of RGS9-2 was
dramatically altered and was now identical to the patchy distri-
bution pattern seen for D2DR (Fig. 4C).
Targeting of DEP domains to D2DR
To identify themolecular domains required for targeting RGS9-2
to D2DR, we created two constructs, DEPless RGS9-2 and the
RGS9 DEP domain (Fig. 3) (see Materials and Methods). When
expressed alone, both protein constructs were distributed uni-
formly throughout the cytoplasm (Fig. 4F,H). Coexpression
with D2DR altered the distribution: the RGS9 DEP domain was
targeted to the distinctive, cytoplasmic compartments expressing
D2DR, whereas the distribution pattern of DEPless RGS9-2 was
unaffected (Fig. 4G,I, respectively), suggesting that the DEP do-
main is both necessary and sufficient for targeting RGS9-2 to
D2DR. The patterns shown here for CHO cells were reproduced
in experiments with HEK 293T and NIH3T3 cell lines (data not
shown).
All results shown are with the D2short (D2s) DR, but identical
results were obtained with D2long DR, which contains 29 addi-
tional amino acids in the third cytoplasmic loop (Missale et al.,
1998), suggesting that this loop plays no important role in the
association with DEP domains. Likewise, a mutant D2sDR lack-
ing the cytoplasmic-tail (1) had wild-type like subcellular distri-
bution and (2)was able to colocalize the RGS9DEPdomain (data
not shown).
DEP domains target to plasmamembrane-localized D2DR
Inmost of the cell lines tested, the fluorescence of the large pool of
intracellular D2DR overwhelmed any signal from plasma
membrane-associated molecules. Do RGS9-2 and D2DR associ-
ate at the plasma membrane, where RGS9-2 presumably func-
tions? We transfected undifferentiated rat pheochromocytoma
12 (PC12) cells with D2DR cDNA using a lipid-mediated trans-
fection protocol. Under these conditions, we found that D2DR
was expressed primarily in the plasma membrane (Fig. 4 J) when
these cells were examined 24–36 h after transfection. RGS9-2 and
DEPless RGS9-2, when expressed alone in these cells, appeared
uniformly through the cytosol (Fig. 4K,M). Coexpression of
D2DR with full-length RGS9-2, but not with DEPless RGS9-2,
resulted in an enriched RGS9-2 signal at the plasma membrane
(compare Figs. 4L, green panel; 3K,M,N, green panels).
Figure 2. Effects of the D2-like DR agonist quinpirole (quin) on excitatory currents elicited
frommedium spiny striatal neurons.A, Representative traces of currents evoked from the same
voltage-clamped (70mV) striatal medium spiny neuron in response to glutamate (glut; 100
M; black trace) or glutamate andquinpirole (glut, 100Mplus quin, 100M; gray trace). Left,
Wild-type neuron; right, RGS9-deficient neuron. Black bars above the traces represent drug
application. B, Glut- and quin-elicited current expressed as a percentage of the current evoked
by glut alone (100M) from wild-type (open bars) and RGS9-deficient (filled black bars) neu-
rons. The mean SEM peak current amplitudes in picoamperes for wild-type cells were: glut
alone, 607 81 (n 9); glut plus 1M quin, 488 63 (n 9); glut plus 10M quin, 574
85 (n 9); glut plus 100M quin, 602 108 (n 9); and for RGS9-deficient cells: glut alone,
31671 (n9); glut plus 1Mquin, 25754 (n8); glut plus 10Mquin, 25052 (n
6); glut plus 100M quin, 155 52 (n 8). C, Current evoked by NMDA (100M; n 7) or
AMPA (10M;n5) in thepresence of quin (100M) expressed as a percentageof the current
evoked, respectively, by NMDA or AMPA alone from RGS9-deficient neurons. Themean SEM
peak current amplitudes in picoamperes were as follows: NMDA alone, 442 106; NMDA plus
quin, 23087;AMPAalone, 26666;AMPAplusquin, 24728. The# symbol indicates that
the quinpirole-sensitive fraction of the current differs significantly from zero. p values using a
paired t test are 0.03, 0.04, and 0.008 at 1, 10, and 100M quinpirole, respectively. The corre-
sponding p values for the wild-type animals were 0.07, 0.8, and 0.9, respectively. The asterisk
indicates that the quinpirole-sensitive fraction of the current differs significantly from the cor-
responding wild-type sample. p 0.01; ANOVA. Error bars represent SEM.
Figure3. Schematic representation (N toC terminus) of theRGS9 constructs. Thenumbers in
parentheses indicate the position of each indicated domain in the original wild-type protein.
The numbers at either end of the openboxes represent the span of thewild-type protein used in
each construct. A, Schematic representation and domain composition of full-length wild-type
RGS9-2. B, The full-length RGS9-2–EGFP fusion construct. The black bar between the RGS9-2
and EGFP represents a flexible spacer/linker with the following sequence: GSGGGSG. C, The
DEPless RGS9-2–EGFP fusion construct in which the N-terminal region of RGS9 containing the
DEP domainwas deleted butwas otherwise identical to the full-length RGS9-2–EGFP fusion.D,
The RGS9 DEP domain fusion construct. The linker represented by the black bar has the follow-
ing sequence: GDPPVAT. GGL, G-protein-subunit-like domain.
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We tested the effect of D2DR agonists
on the colocalization of D2DR and DEP
domain-containing constructs. Cells were
incubated with dopamine (1 M), apo-
morphine (1M), or quinpirole (1M) for
periods ranging from 5 min to 24 h. These
D2DR agonists did not affect the cellular
distribution of D2DR or the association
between D2DR and DEP domains in PC12
cells or CHO cells (data not shown).
Functional effects of
D2DR–RGS9-2 colocalization
RGS9-2 did not colocalize detectably to
any other GPCRs that were screened.
These included (1) the Gq-coupled m1-
mAChR, the cellular expression pattern of
which matches that of D2DR (Fig. 5A,B),
(2) the Gs-coupled D1 dopamine receptor
(Fig. 5C,D), and (3) the Gi- and Go-
coupled m2-mAChR (Fig. 5E,F).
We used the Xenopus oocyte system to
suggest a functional consequence for this
specific DEP domain-dependent localiza-
tion of RGS9-2 to D2DR. It is appropriate
to assay for the GTPase-enhancing prop-
erty of RGS proteins by measuring the ac-
celerated deactivation of coexpressed
GIRK channels (Doupnik et al., 1997; Ko-
voor et al., 2000; Rahman et al., 2003). Fig-
ure 5,G andH, depicts representative nor-
malized traces of deactivation waveforms
for dopamine-evoked (100 nM; red trace)
and acetylcholine-evoked (100 nM; black
trace) GIRK currents recorded from the
oocyte group expressing the appropriate
receptor and either RGS9-2 (Fig. 5G) or
DEPless RGS9-2 (Fig. 5H). For several
RGSs including RGS9, deletions
N-terminal to the RGS domain enhanced
the intrinsic GTPase-enhancing function
of the RGS protein (Fig. 5H, I) (Kovoor et
al., 2000; A. Kovoor and H. A. Lester, un-
published observations). Thus, the func-
tional consequence of the failure of DEP-
less RGS9-2 to colocalize with D2DR
would be obscured by the increased intrin-
sic activity of the DEPless construct, vitiat-
ing direct comparisons between the action
of RGS9-2 and DEPless RGS9-2 on the
D2DR response. Instead, comparisons
were made between signaling by D2DR
and m2-mAChR, because the latter GPCR
displays no RGS9-2 colocalization (Fig.
5E,F).
Although the intrinsic deactivation
rates (in the absence of RGS9) of theD2DR
and m2-mAChR response were similar, the RGS9-2-mediated
acceleration of the deactivation rate was significantly greater for
the D2DR response (Fig. 5G,I). DEPless RGS9-2 also accelerated
the deactivation kinetics of both the D2DR-elicited and m2-
mAChR-elicited GIRK response (Fig. 5H, I). However, in con-
trast to observations with full-length RGS9-2, the acceleration of
the deactivation rates of the D2DR response was not significantly
different from the deactivation rate for the m2-mAChR response
(Fig. 5I). Thus, full-length RGS9-2 preferentially accelerates the
deactivation of D2DR-elicited responses, whereas DEPless
RGS9-2 does not. To prevent several classes of artifacts, the ratios
of receptor and GIRK cRNA injected were chosen so that (1) the
Figure 4. Distribution of D2DR and RGS9-2 in transfected CHO and PC12 cells. D2DR distribution is depicted in red, whereas
RGS9-2 constructs and EGFP are shown in green.A, D2DR distribution in CHO cells thatwere transfectedwith cDNA for D2DR alone.
B, RGS9-2 distribution in CHO cells that were transfected with cDNA for the RGS9-2 alone. C, D2DR distribution (red; left) and
RGS9-2 distribution (green; right) in CHO cells transfected with cDNA for both D2DR and the RGS9-2. D, EGFP distribution in CHO
cells transfected with cDNA for EGFP alone. E, D2DR distribution (red; left) and EGFP distribution (green; right) in CHO cells
transfected with cDNA for both D2DR and EGFP. F, DEPless RGS9-2 distribution in CHO cells that were transfected with cDNA for
DEPless RGS9-2. G, D2DR distribution (red; left) and DEPless RGS9-2 distribution (green; right) in CHO cells transfected with cDNA
for bothD2DRandDEPless RGS9-2.H, RGS9DEPdomaindistribution in CHO cells thatwere transfectedwith cDNA for theRGS9DEP
domain alone. I, D2DR distribution (red; left) and RGS9 DEP domain distribution (green; right) in CHO cells transfected with cDNA
for both D2DR and RGS9 DEP domain. J, D2DR distribution in PC12 cells thatwere transfectedwith cDNA for D2DR alone.K, RGS9-2
distribution in PC12 cells that were transfected with cDNA for the RGS9-2 fusion protein alone. L, D2DR distribution (red; left)
and RGS9-2 distribution (green; right) in PC12 cells transfected with cDNA for both D2DR and the RGS9-2 fusion construct.
M, DEPless RGS9-2 distribution in PC12 cells that were transfected with cDNA for DEPless RGS9-2. N, D2DR distribution (red; left)
and DEPless RGS9-2 distribution (green; right) in PC12 cells transfectedwith cDNA for both D2DR andDEPless RGS9-2. The left and
right pictures, respectively, in panels C, E, G, I, L, and N represent confocal scans of the same field. Outlines of cells in which the
specific fluorescent signal does not extend to the cell boundary are marked out with a yellow dashed line. Each CHO cell image is
representative of the distribution pattern in90% of cells in at least five observed fields, each containing50 cells transfected
with the relevant constructs. For PC12 cells, each image is representative of the distribution pattern observed in90% of
cells from at least 20 observed fields, each containing at least one cell transfected with the relevant constructs. Scale bar:
(in A) A–N, 5m.
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level of expressed receptor and not of
GIRK channel was limiting, (2) the GIRK
responses elicited by m2-mAChR and
D2DRwere comparable, and (3) all kinetic
measurements were well resolved by our
changes.
Discussion
DEP domain GPCR interactions
are specific
The observations that the EGFP tag was
not colocalized toD2DR and that its distri-
bution was not altered by coexpressed
D2DR argue for a specific interaction be-
tween D2DR and EGFP-tagged RGS9-2
(Fig. 4D,E). In addition, an RGS9-2 con-
struct lacking the DEP domain did not co-
localize with D2DR. In fact, the RGS9 DEP
domain is both necessary and sufficient for
targeting RGS9-2 to the cellular regions
expressing D2DR (Fig. 4F–I). Also,
RGS9-2 (Fig. 5) and the RGS9 DEP do-
main (data not shown) did not colocalize
with m1-mAChR (Fig. 5A,B), which had
an expression pattern comparable with
that of D2DR in CHO cells or with D1DR
(Fig. 5C,D). Thus, overexpression of a
GPCR did not guarantee association. Fi-
nally, a construct containing a mutated
DEP domain (F115S; data not shown)
failed to relocalize to coexpressed D2DR.
These data point to a specific targeting
of RGS9-2 to D2DR and exclude coinci-
dental colocalization, because the distri-
bution of full-length RGS9-2 and the DEP
domain was altered by D2DR coexpres-
sion. After D2DR coexpression, DEP
domain-containing constructs were relo-
cated to the compartment expressing
D2DR (i.e., to the plasma membrane in
PC12 cells and to the D2DR-expressing cy-
toplasmic compartments in other cell
types). If the interaction between RGS9-2
and D2DR occurs via a third protein, this
additional protein is expressed in all cell
types that were examined.
GPCR, RGS proteins, and
signal specificity
This study suggests how RGS regulation
can be targeted to a specific G-protein-
coupled receptor pathway. The agonist-
independent, DEP domain-dependent co-
localization positions RGS9-2 close to the
D2DR-coupled G subunits. After G
subunits are released by activated D2DRs,
the proximity of RGS9-2 to D2DR allows
RGS9-2 to readily interact with and inac-
tivate these nearby G-protein subunits.
The functional effects of such colocaliza-
tion become evenmore prominent in neu-
rons, which have a more complex mor-
phology than Xenopus oocytes and have
Figure 5. Distribution ofm1-mAChR, D1DR,m2-mAChR, and RGS9-2 in transfected CHO cells and effect of RGS9-2 and DEPless
RGS9-2 on the deactivation kinetics of D2DR- or m2-mAChR-elicited GIRK currents in Xenopus oocytes. A, m1-mAChR (labeled
m1-mR) distribution in cells that were transfected with cDNA for D2DR alone. B, m1-mR distribution (red; left) and RGS9-2
distribution (green; right) in cells transfected with cDNA for both m1-mR and RGS9-2. C, D1DR distribution in cells that were
transfected with cDNA for D1DR alone. D, D1DR distribution (red; left) and RGS9-2 distribution (green; right) in cells transfected
with cDNA for both D1DR and the RGS9-2. E,m2-mAChR (labeledm2-mR) distribution in cells thatwere transfectedwith cDNA for
D2DR alone. F, m2-mR distribution (red; left) and RGS9-2 distribution (green; right) in cells transfected with cDNA for both D2DR
and RGS9-2. The left and right pictures, respectively, in B, D, and F represent confocal scans of the same field. Outlines of cells in
which the fluorescence does not extend to the cell boundary are marked out with a yellow dashed line. Each image is represen-
tative of the distribution pattern in90% of cells in at least five observed fields, each containing50 cells transfectedwith the
relevant constructs. Scale bar: (in A) A–F, 5m. In the Xenopus oocyte experiments, control oocytes were injectedwith cRNA for
m2-mR, GIRK1, andGIRK2 orwith cRNA for D2DR, GIRK1, andGIRK2. Someoocytes in each of the control groupswere also injected
with cRNA for either RGS9-2 or for the DEPless RGS9-2. G, H, Representative normalized traces of deactivation waveforms for
dopamine-evoked (dop; D2DR agonist; 100 nM; red trace) and acetylcholine-evoked (m2-mR agonist; 100 nM; black trace) GIRK
currents recorded from the oocyte group expressing the appropriate receptor and either RGS9-2 (G) or DEPless RGS9-2 (H ). The
horizontal bar above the traces represents either dopamine or acetylcholine application. I, Deactivation rate constants, koff
(1/deactivation), were from exponential fits of the deactivation phase of the GIRK currents. For each receptor, acceleration of
deactivation by RGS9-2was calculated as follows: (individual values for koff in the oocytes injectedwith RGS9-2 cRNA)/(mean koff
in the corresponding control group lacking RGS9-2). Acceleration of deactivation by DEPless RGS9-2 was calculated similarly. All
bars are means SEM from the same oocyte donor (red open bar, D2DR response; black open bar, m2-mR response; * indicates
significant difference; p 0.05; Student’s t test). In the experimentmeasuring RGS9-2-mediated acceleration of the deactivation
kinetics, themean SEM koff values in seconds
1 for the different oocyte groupswere as follows: D2DR, 0.057 0.006 (n 4);
D2DRplus RGS9-2, 0.1020.007 (n5);m2-mR, 0.0550.003 (n5);m2-mRplus RGS9-2, 0.0780.004 (n5), and the
mean SEM steady-state current amplitudes in nanoamperes were: D2DR, 1094 284; D2DR plus RGS9-2, 1125 128;
m2-mR,1460153;m2-mRplusRGS9-2, 1416102. In theexperimentmeasuringDEPlessRGS9-2-mediatedacceleration, the
mean SEM koff values in seconds
1 were as follows: D2DR, 0.131 0.021 (n 5); D2DR plus DEPless RGS9-2, 0.211 0.014
(n 8); m2-mR, 0.123 0.008 (n 12); m2-mR plus DEPless RGS9-2, 0.225 0.007 (n 12), and the mean SEM
steady-state current amplitudes in nanoamperes were: D2DR, 618 43; D2DR plus DEPless RGS9-2, 943 158; m2-mR, 964
90; m2-mR plus DEPless RGS9-2, 953 92. Error bars represent SEM.
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specialized regions such as axon terminals, initial segments, and
dendrites. Our model provides a molecular explanation for two
recently published studies. In one study, viral-mediated overex-
pression of RGS9-2, but not RGS4, in rat ventral striatum, re-
duced locomotor responses specifically to D2DR agonists (Rah-
man et al., 2003). In another study, RGS9 reduced D2DR
modulation of Cav2.2 channels but did not alter m2-muscarinic
receptor modulation of Cav2.2 currents in the same neuron
(Cabrera-Vera et al., 2004).
Implications for synaptic modulation by D2DRs
Our use of GIRK channels in the Xenopus oocyte experiments
(Fig. 5) does not suggest that they are effector molecules for
D2DRs in the striatum. In fact, the effector molecules important
in striatal D2-like DR signaling pathways have not been identified
(Nicola et al., 2000). However, D2-like DRs in the striatum signal
via heterotrimeric G-proteins and GIRK channels are activated
by these same G-proteins (Dascal, 2001). Previously, we have
shown that the activation of coexpressed GIRK channels is a sen-
sitive measure of the physiologically relevant activation of
G-proteins and of RGS function (Kovoor et al., 2000). Similarly,
in this study, these channels were used to show that the DEP
domain-mediated localization of RGS9 to D2DRs can have func-
tional consequences for G-protein-mediated D2DR signaling.
Both excitatory glutamatergic inputs from the cortex and do-
paminergic inputs from the substantia nigra make synaptic con-
tacts with the medium spiny neuron (Gerfen, 1992), which ex-
press glutamate receptor subunits and dopamine receptors. Our
data clearly demonstrate that RGS9 is an important regulator of
the neuronal pathways that modulate the membrane conduc-
tances elicited by NMDA-type glutamate receptor activation.
This modulation may be important in drug-induced dyskinesia,
because recent study in primates indicates that levodopa-induced
dyskinesias can be modulated via NMDA and AMPA receptors.
Antagonists of AMPA receptors reduce D1DR agonist-induced
dyskinesias, and antagonists of NMDA receptors reduce D2DR
agonist-induced dyskinesia (Bibbiani et al., 2004). In addition,
hemiparkinsonian rats chronically treated with levodopa also
show abnormal phosphorylation of NMDA receptors (Dunah et
al., 2000). The present experiments also provide the first physio-
logically relevant description of a cellular function for an RGS
protein in the brain.
Because voltage-clamp recordings in neurons can be limited
by inadequate space clamp, it is possible that glutamate applica-
tion strongly depolarized regions of the neurons, locally activat-
ing voltage-dependent channels. Conceivably then, it is not the
NMDA receptors but these secondary conductances that are in-
hibited by quinpirole in striatal slices from the RGS9 knock-out
animals, and NMDA and AMPA receptors are differentially lo-
calized to the extent that they activate distinct secondary conduc-
tance. Thus, although our data indicate that the striatal signal
transduction pathways modulated by RGS9-2 are closely associ-
ated with NMDA but not AMPA receptors, a direct interaction
between the dopaminergic and glutamatergic receptors cannot
yet be claimed.
Pharmacological tests do not distinguish conclusively be-
tween the D2DRs and the other D2-class DRs (D3 and D4). Drug-
induced dyskinesias are elicited by agonists and antagonists act-
ing on allmembers of theD2 class of dopamine receptors, and the
contributions of D2 versus D3 versus D4 receptors for the patho-
genesis of this condition is not clear. Therefore, discrimination of
the effect of lack of RGS9 onmodulation of signaling via individ-
ualmembers of theD2-class receptors was not within the scope of
the present study.
D2-like DRs are thought to be expressed by a subset (50–
60%) of striatal medium spiny neurons (Gerfen, 1992; Surmeier
et al., 1996). In accordance with this idea, the fraction of RGS9-
null striatal neurons that showed25% inhibition of glutamate-
elicited currents was 0.5 at 1 M quinpirole, a concentration of
quinpirole that is specific for D2-like DRs. All of the RGS9-null
cells responded to 100 M quinpirole, possibly because of non-
specific effects at this quinpirole concentration. Alternatively, the
absence of RGS9 might allow for the functional detection of low
levels of D2-class receptors that are ordinarily not detected. This
suggestion is supported by a recent study by Aizman and col-
leagues, which found that virtually all striatal neurons, both in
vitro and in vivo, contained dopamine receptors of both classes
(Aizman et al., 2000).
The relationship between the abnormal electrophysiology in
the striatal neurons from the RGS9 knock-out mice and the ab-
normal behavior detected after dopamine depletion or neurolep-
tic treatment remains to be elucidated. Unfortunately, electro-
physiological recordings in mutant mice were successful only in
animals younger than 4 weeks. Thus, all electrophysiological data
were taken in animals that were not weaned and hence were too
young to reproduce the behavioral abnormalities that we de-
tected in older animals. However, these data are a first step to-
ward understanding the cellular mechanisms for the locomotor
abnormalities observed in the older RGS9-null mice.
Amodel for dyskinesias?
There are few animal models for drug-induced dyskinesias
(Kulkarni and Naidu, 2001), and the abnormal involuntary
movements described in this study (Fig. 1)more closely resemble
drug-induced dyskinesia in humans than other reported rodent
models such as vacuous chewing (Andreassen et al., 2001).
Direct treatment of the knock-out mice with D2DR agonists
only produced minor increases in locomotion. Disorders similar
to the drug-induced dyskinesias were produced exclusively in
RGS9 knock-out mice and only when D2DR agonist treatment
was preceded by a prolonged inhibition of dopaminergic trans-
mission (see Materials and Methods). There is evidence that
chronic inhibition of dopamine signaling along the nigrostriatal
dopamine pathway can produce D2DR supersensitivity (i.e., en-
hanced cellular signaling) that may result from an increase in the
number of striatal D2DR (Rubinstein et al., 1990; LaHoste and
Marshall, 1994).
RGS9-2 could suppress these abnormal movements via either
of twomechanisms. By accelerating the termination of G-protein
signals, RGS proteins attenuate the integrated cellular effects of
G-protein activation (Ross andWilkie, 2000). RGS9-2 andD2DR
are found coexpressed in striatal medium spiny neurons (Rah-
man et al., 2003), and RGS9-2 can accelerate the termination of
D2DR signals (Fig. 5E,F). Because RGS9-2 is targeted to D2DR
via the RGS9-2 DEP domain, it is well situated to influence any
functional effects of altered D2DR expression that may result
from prolonged antipsychotic treatment (Rubinstein et al., 1990;
LaHoste and Marshall, 1994). Thus, drugs targeting RGS9-2
might be useful in the treatment of dyskinesias (Neubig and Sid-
erovski, 2002).
Alternatively, the RGS9 DEP domain in conjunction with
other proteins may compartmentalize D2-like DRs so as to pre-
vent D2-like DR-mediated inhibition of NMDA-elicited conduc-
tances. Prolonged inhibition of dopaminergic signaling could al-
ter expression levels of either D2DR or RGS9-2 so as to disrupt
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such compartmentalization, leading to an abnormal signaling
and abnormal involuntary movements.
In our RGS9 knock-out mouse model, we elicited abnormal
movements after only 3 d of drug treatment. Dyskinesias in hu-
man patients occur only aftermonths, if not years, of therapy and
may reflect the time required for significant alterations in striatal
D2DR or RGS9-2. The speedier onset of abnormal movements in
the RGS9 knock-out mice may result from the complete loss of
RGS9-2 expression resulting from the genetic ablation ofRGS9. If
dysregulation of RGS9 contributes to drug-induced dyskinesia in
humans, alterations are presumablymore subtle and require time
to develop.
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